Sclerosis lateralis amyotrophica

Sclerosis lateralis amyotrophica^[1] (ICD-10: G12.2) est gravis morbus systematis nervosi, accurate neuronum motoriorum defectio. Hic morbus, qui corpus degenerat dum progreditur, adhuc hodie sanari non potest, et ad extremum in mortem ducit. Primum hunc morbum descripsit Ioannes Martinus Charcot, medicus Francicus.

Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.

In Italia multi pedilusores hoc morbo mortui sunt, ergo putatur, ut fortasse venena contra mala gramina adhibita, quae in pediludii campis utuntur, sclerosem lateralem amyotrophicam generare possint.^[2] Non est remedium sanans, at ad morbum allevandum inter alia technologia adiuvans vel communicatio augmentans et alternativa utitur.

Symptomata et signa

Neuronibus motoriis et superioribus et inferioribus degeneratis symptomata ac signa musculorum et tenuitas (atrophia) et infirmitas corporis apparent. Cum initium haud raro obscurum est, in morbi cursu symptomata muscularia progrediuntur. Adhuc omnibus rationibus infrenatis postremo morbus quamcumque paene gubernationem motuum voluntariam aufert. Musculorum bulbi oculi externorum gubernatio autem saepe usque ad extremum intacta restat sicut et functio musculorum levium in tractibus gastrintestinali et urogenoitali.^[3].

Nuper sclerosem lateralem amyotrophicam etiam symptomata obstringere prospectatum est. Symptomata psychiatrica ut schizophreniae vel mali affectionis iam descripta sunt^[4]. Porro nexus cum degeneratione lobulari frontotemporali suspicatus est.

Neuropathologia

Ad gradus morbi neuropathologiae definienda proteinum TDP-43 aliquantum valere videtur^[5]. Itemque aggregationes SOD1 (superoxidi dismutasis), C9orf72 (Chromosomatis 9 margo lectoria aperta 72), et FUS (ARN ligans proteinum FUS) descriptae sunt^[6].

Tractatio

Adhuc methodus curandi incognita est. In therapia hodierna medicamentum Riluzolum adhiberi licet, quod decursum paulum tardat^[7].

Homines notabiles affecti

Notae

↑ Dissertatio, www.researchgate.net.
↑ M. Vinceti, I. Bottecchi, A. Fan, Y. Finkelstein, J. Mandrioli (2012): Are environmental exposures to selenium, heavy metals, and pesticides risk factors for amyotrophic lateral sclerosis? In: Rev Environ Health, vol. 1, pp. 19-41.
↑ Hobson E. V., McDermott C. J. (2016). "Supportive and symptomatic management of amyotrophic lateral sclerosis". Nat Review of Neurology 12: 526-38 .
↑ Zucchi E., Ticozzi N., Mandrioli J. (2019). "Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder". Frontiers in neuroscience 13: 175
↑ Brettschneider J., Del Tredici K., Toledo J. B., Robinson J. L., Irwin D. J., Grossman M., Suh E., Van Deerlin V. M., et al. (2013). "Stages of pTDP-43 pathology in amyotrophic lateral sclerosis". Annals in neurology 74 (1): 20-38
↑ Koski L., Ronnevi C., Berntsson E., et al. (Nov 2021). "Metals in ALS TDP-43 Pathology". International journal of molecular sciences 22 (22): 12193 doi:10.3390/ijms222212193
↑ Miller R. G., Mitchell J. D., Moore D. H. (Mar 2012). "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)". The Cochrane database of systematic reviews (3): )CD001447

Nexus interni

Nexus externi

Vicimedia Communia plura habent quae ad Sclerosem lateralem amyotrophicam spectant.

National Institute of Neurological Disores an Stroke:De Sclerose laterali amyotrophica(Anglice)

stipula

Haec stipula ad medicinam spectat. Amplifica, si potes!

[1] Dissertatio, www.researchgate.net.

[2] M. Vinceti, I. Bottecchi, A. Fan, Y. Finkelstein, J. Mandrioli (2012): Are environmental exposures to selenium, heavy metals, and pesticides risk factors for amyotrophic lateral sclerosis? In: Rev Environ Health, vol. 1, pp. 19-41.

[3] Hobson E. V., McDermott C. J. (2016). "Supportive and symptomatic management of amyotrophic lateral sclerosis". Nat Review of Neurology 12: 526-38 .

[4] Zucchi E., Ticozzi N., Mandrioli J. (2019). "Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder". Frontiers in neuroscience 13: 175

[5] Brettschneider J., Del Tredici K., Toledo J. B., Robinson J. L., Irwin D. J., Grossman M., Suh E., Van Deerlin V. M., et al. (2013). "Stages of pTDP-43 pathology in amyotrophic lateral sclerosis". Annals in neurology 74 (1): 20-38

[6] Koski L., Ronnevi C., Berntsson E., et al. (Nov 2021). "Metals in ALS TDP-43 Pathology". International journal of molecular sciences 22 (22): 12193 doi:10.3390/ijms222212193

[7] Miller R. G., Mitchell J. D., Moore D. H. (Mar 2012). "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)". The Cochrane database of systematic reviews (3): )CD001447

[1]

[2]

[3]

[4]

[5]

[6]

[7]